Raymond James & Associates’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Raymond James & Associates’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-800	Closed	-$2K	–	3823
2019 Q1	$2K	Hold	800	–	–	﹤0.01%	3604
2018 Q4	$2K	Hold	800	–	–	﹤0.01%	3519
2018 Q3	$4K	Hold	800	–	–	﹤0.01%	3609
2018 Q2	$4K	Hold	800	–	–	﹤0.01%	3560
2018 Q1	$6K	Hold	800	–	–	﹤0.01%	3426
2017 Q4	$6K	Hold	800	–	–	﹤0.01%	3395
2017 Q3	$7K	Hold	800	–	–	﹤0.01%	3370
2017 Q2	$8K	Hold	800	–	–	﹤0.01%	3305
2017 Q1	$9K	Hold	800	–	–	﹤0.01%	3243
2016 Q4	$10K	Sell	800 -50	-6%	-$793	﹤0.01%	3192
2016 Q3	$16K	Hold	850	–	–	﹤0.01%	3149
2016 Q2	$9K	Hold	850	–	–	﹤0.01%	2972
2016 Q1	$16K	Buy	+850	New	+$16.4K	﹤0.01%	2870

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's NAVB Position: Q2 2019 in Review

Raymond James & Associates sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 800 shares — an estimated $2K sold.

Raymond James & Associates first reported a position in NAVB in Q1 2016 and held it in 13 quarters. The position peaked at $16K in Q3 2016. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

Raymond James & Associates reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Raymond James & Associates sold 800 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $2K.
Raymond James & Associates first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2016 and held it in 13 quarters.
Raymond James & Associates's Navidea Biopharmaceuticals Inc. position peaked at $16K in Q3 2016.
27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.